Sana Biotechnology, Inc.
SANAHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. The $876.6M market capitalization puts SANA squarely in small-cap range for its industry. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Market Cap
$876.6M
Beta
2.14
P/E (TTM)
—
P/E (Fwd)
-6.03
EPS (TTM)
$-0.91
EPS (Fwd)
$-0.52
ROE
-147.4%
ROA
-27.5%
Cash
$101.1M
Total Debt
$82.6M
Free CF
-$29.7M
52W Change
-32.0%
Annual Financials
Cash vs Debt
With $101.1M in cash and $82.6M in debt, SANA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$29.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -147.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.14 means SANA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Sana Biotechnology, Inc. and its sector.